

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

<https://marketpublishers.com/r/G22CBF77F5FDEN.html>

Date: November 2024

Pages: 498

Price: US\$ 4,950.00 (Single User License)

ID: G22CBF77F5FDEN

Abstracts

The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period.

Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.

“The product segment accounted for the largest share by offerings segment in the gene editing market in 2023”

By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutical & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.

“The CRISPR technology held the highest market share of the gene editing products market by technology in 2023”

By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.

“The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029.”

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,

By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

Thermo fisher scientific Inc. (US)

Merck KGaA (Germany)

GenScript (US)

Agilent Technologies, Inc. (US)

Revvity (US)

Lonza (US)

Tecan Trading AG (Switzerland)

Sangamo therapeutics (US)

Precision BioSciences (US)

Cellectis S.A. (France)

Regeneron Pharmaceuticals Inc. (US)

AMSBIO (UK)

Creative Biogene (US)

Synthego (US)

Takara Bio Inc. (Japan)

Bio-Techne (US)

Caribou Biosciences, Inc. (US)

Bioneer corporation (South Korea)

REPROCELL Inc. (Japan)

Research Coverage:

This research report categorizes the gene editing market by offerings (products and services), products by type (reagents & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities

(Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly launched product/services of the gene editing market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the gene editing market

Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland), Sangamo therapeutics (US). Precision BioSciences (US), Collectis S.A. (France), Regeneron Pharmaceuticals Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego (US), Takara Bio Inc. (Japan), Bio-Techne (US), Caribou Biosciences, Inc. (US) Bioneer corporation (South Korea), and REPROCELL Inc. (Japan).

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 LIMITATIONS
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 MARKET ESTIMATION
 - 2.2.1.1 Insights of primary experts
 - 2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 GENE EDITING MARKET OVERVIEW
- 4.2 NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023)
- 4.3 GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing demand for personalized medicine

5.2.1.2 Favorable government funding investments for gene editing projects

5.2.1.3 Expanding applications of gene editing

5.2.2 RESTRAINTS

5.2.2.1 Off-target effects and safety concerns

5.2.3 OPPORTUNITIES

5.2.3.1 Rising technological advancements in prime editing and bridge RNA

5.2.3.2 Increasing burden of congenital disorders

5.2.4 CHALLENGES

5.2.4.1 Issues associated with scalability of gene editing workflows

5.2.4.2 High equipment & manufacturing costs

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.4 PRICING ANALYSIS

5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE
(2023)

5.4.2 AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021?2023

5.4.3 AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE

5.4.4 AVERAGE SELLING PRICE, BY REGION

5.5 SUPPLY CHAIN ANALYSIS

5.6 VALUE CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

5.8 IMPACT OF GENERATIVE AI ON GENE EDITING MARKET

5.9 TECHNOLOGY ANALYSIS

5.9.1 KEY TECHNOLOGIES

5.9.1.1 Next-generation sequencing

5.9.1.2 Electroporation

5.9.1.3 Microinjection

5.9.2 COMPLEMENTARY TECHNOLOGIES

5.9.2.1 Synthetic biology

5.9.2.2 Data analysis

5.9.2.3 High-throughput screening

5.9.3 ADJACENT TECHNOLOGIES

5.9.3.1 Single-cell analysis

5.9.3.2 Optogenetics

5.9.3.3 Gene delivery systems

5.10 PATENT ANALYSIS

5.11 KEY CONFERENCES AND EVENTS, 2024?2025

5.12 REGULATORY ANALYSIS

5.12.1 REGULATORY LANDSCAPE

5.12.1.1 North America

5.12.1.1.1 US

5.12.1.1.2 Canada

5.12.1.2 Europe

5.12.1.2.1 UK

5.12.1.3 Asia Pacific

5.12.1.3.1 China

5.12.1.3.2 Japan

5.12.1.3.3 South Korea

5.12.1.3.4 Australia

5.12.1.3.5 Rest of Asia Pacific

5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.13 PORTER'S FIVE FORCES ANALYSIS

5.13.1 THREAT OF NEW ENTRANTS

5.13.2 THREAT OF SUBSTITUTES

5.13.3 BARGAINING POWER OF BUYERS

5.13.4 BARGAINING POWER OF SUPPLIERS

5.13.5 INTENSITY OF COMPETITIVE RIVALRY

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.14.2 KEY BUYING CRITERIA

5.15 CASE STUDY ANALYSIS

5.15.1 ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID ssDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS

5.15.2 GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA

5.15.3 DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PURECUT CRISPR CAS9 RNP SYSTEM

5.15.4 EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING

5.15.5 GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS

5.16 INVESTMENT & FUNDING SCENARIO

5.16.1 KEY INVESTMENTS & FUNDING ACTIVITIES, 2021?2024

5.17 TRADE DATA ANALYSIS

5.17.1 IMPORT DATA, 2019?2023

5.17.2 EXPORT DATA, 2019?2023

6 GENE EDITING MARKET, BY OFFERING

6.1 INTRODUCTION

6.2 PRODUCTS

6.2.1 EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO DRIVE MARKET

6.3 SERVICES

6.3.1 HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET

7 GENE EDITING PRODUCTS MARKET, BY TYPE

7.1 INTRODUCTION

7.2 REAGENTS & CONSUMABLES

7.2.1 GENE EDITING KITS

7.2.1.1 Increasing demand for mutation & screening kits in clinical settings to propel market

7.2.2 GENE EDITING LIBRARIES

7.2.2.1 Genetic screening for cancer research to fuel uptake

7.2.3 GENE EDITING REAGENTS

7.2.3.1 Ability to create animal models to support market growth

7.3 SOFTWARE & SYSTEMS

7.3.1 INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET

8 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE

8.1 INTRODUCTION

8.2 KNOCK-OUT

8.2.1 MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET

8.3 KNOCK-IN

8.3.1 UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO DRIVE MARKET

8.4 GENE SILENCING

8.4.1 ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO

SUPPORT MARKET GROWTH

8.5 OTHER TECHNIQUES

9 GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY

9.1 INTRODUCTION

9.2 CRISPR

9.2.1 ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE

9.3 TALENS

9.3.1 INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET

9.4 ZFN

9.4.1 PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO BOOST DEMAND

9.5 BASE EDITING

9.5.1 GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET

9.6 ANTISENSE

9.6.1 INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH

9.7 RNAI

9.7.1 WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE

9.8 OTHER TECHNOLOGIES

10 GENE EDITING PRODUCTS MARKET, BY APPLICATION

10.1 INTRODUCTION

10.2 CELL LINE ENGINEERING

10.2.1 ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION TO DRIVE MARKET

10.3 GENOME EDITING

10.3.1 GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND

10.4 DRUG DISCOVERY & DEVELOPMENT

10.4.1 UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO DRIVE MARKET

10.5 OTHER APPLICATIONS

11 GENE EDITING PRODUCTS MARKET, BY END USER

11.1 INTRODUCTION

11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET

11.3 ACADEMIC & RESEARCH INSTITUTES

11.3.1 FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET

11.4 CROS & CDMOS

11.4.1 PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO DRIVE MARKET

11.5 OTHER END USERS

12 GENE EDITING SERVICES MARKET, BY TYPE

12.1 INTRODUCTION

12.2 CELL LINE DEVELOPMENT & ENGINEERING

12.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET

12.3 GRNA SYNTHESIS & VECTOR CONSTRUCTION

12.3.1 ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET

12.4 LIBRARY CONSTRUCTION & SCREENING

12.4.1 INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET

12.5 OTHER SERVICES

12.5.1 OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES.

13 GENE EDITING SERVICES MARKET, BY APPLICATION

13.1 INTRODUCTION

13.2 CELL LINE ENGINEERING

13.2.1 HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET

13.3 GENOME EDITING

13.3.1 GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND

13.4 DRUG DISCOVERY & DEVELOPMENT

13.4.1 GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE

13.5 OTHER APPLICATIONS

14 GENE EDITING SERVICES MARKET, BY END USER

14.1 INTRODUCTION

14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

14.2.1 GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET

14.3 ACADEMIC & RESEARCH INSTITUTES

14.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET

14.4 OTHER END USERS

15 GENE EDITING MARKET, BY REGION

15.1 INTRODUCTION

15.2 NORTH AMERICA

15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

15.2.2 US

15.2.2.1 Growing investments by government authorities and private players to drive market

15.2.3 CANADA

15.2.3.1 Rise in research & development initiatives for genomics and biotechnology to augment growth

15.3 EUROPE

15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

15.3.2 GERMANY

15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market

15.3.3 FRANCE

15.3.3.1 Ongoing clinical trials and advanced genomic research to promote growth

15.3.4 UK

15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market

15.3.5 ITALY

15.3.5.1 Increasing availability of research funds to expedite growth

15.3.6 SPAIN

15.3.6.1 Booming biotechnology sector to contribute to market growth

15.3.7 REST OF EUROPE

15.4 ASIA PACIFIC

15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

15.4.2 CHINA

15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth

15.4.3 JAPAN

15.4.3.1 Growing focus on cancer research to fuel market

15.4.4 INDIA

15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth

15.4.5 SOUTH KOREA

15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth

15.4.6 AUSTRALIA

15.4.6.1 Favorable regulatory landscape to sustain growth

15.4.7 REST OF ASIA PACIFIC

15.5 LATIN AMERICA

15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

15.5.2 BRAZIL

15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market

15.5.3 REST OF LATIN AMERICA

15.6 MIDDLE EAST

15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

15.6.2 GCC COUNTRIES

15.6.2.1 Kingdom of Saudi Arabia

15.6.2.1.1 Increasing establishment of biotech startups to support market growth

15.6.2.2 United Arab Emirates (UAE)

15.6.2.2.1 Growing collaborations for genome sequencing to drive market

15.6.2.3 Other GCC Countries

15.6.3 REST OF MIDDLE EAST

15.7 AFRICA

15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH

15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

16 COMPETITIVE LANDSCAPE

16.1 INTRODUCTION

16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021?2024

16.3 REVENUE ANALYSIS, 2019?2023

16.4 MARKET SHARE ANALYSIS, 2023

- 16.4.1 RANKING OF KEY MARKET PLAYERS
- 16.5 COMPANY VALUATION AND FINANCIAL METRICS
 - 16.5.1 COMPANY VALUATION
 - 16.5.2 FINANCIAL METRICS
- 16.6 BRAND/PRODUCT COMPARISON
 - 16.6.1 THERMO FISHER SCIENTIFIC INC. (US)
 - 16.6.2 MERCK KGAA (GERMANY)
 - 16.6.3 GENSCRIPT (US)
 - 16.6.4 AGILENT TECHNOLOGIES, INC. (US)
 - 16.6.5 REVVITY, INC. (US)
- 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
 - 16.7.1 STARS
 - 16.7.2 EMERGING LEADERS
 - 16.7.3 PERVASIVE PLAYERS
 - 16.7.4 PARTICIPANTS
 - 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
 - 16.7.5.1 Company footprint
 - 16.7.5.2 Product footprint
 - 16.7.5.3 Service footprint
 - 16.7.5.4 Technology footprint
 - 16.7.5.5 Region footprint
- 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 - 16.8.1 PROGRESSIVE COMPANIES
 - 16.8.2 RESPONSIVE COMPANIES
 - 16.8.3 DYNAMIC COMPANIES
 - 16.8.4 STARTING BLOCKS
 - 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
 - 16.8.5.1 Detailed list of key startups/SMEs
 - 16.8.5.2 Competitive benchmarking of key startups/SMEs
- 16.9 COMPETITIVE SCENARIO
 - 16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
 - 16.9.2 DEALS
 - 16.9.3 EXPANSIONS

17 COMPANY PROFILES

- 17.1 KEY PLAYERS
 - 17.1.1 THERMO FISHER SCIENTIFIC INC.
 - 17.1.1.1 Business overview

- 17.1.1.2 Products/Services offered
- 17.1.1.3 Recent developments
 - 17.1.1.3.1 Product/Service launches & approvals
 - 17.1.1.3.2 Deals
 - 17.1.1.3.3 Expansions
- 17.1.1.4 MnM view
 - 17.1.1.4.1 Key strengths
 - 17.1.1.4.2 Strategic choices
 - 17.1.1.4.3 Weaknesses & competitive threats
- 17.1.2 MERCK KGAA
 - 17.1.2.1 Business overview
 - 17.1.2.2 Products/Services offered
 - 17.1.2.3 Recent developments
 - 17.1.2.3.1 Deals
 - 17.1.2.4 MnM view
 - 17.1.2.4.1 Key strengths
 - 17.1.2.4.2 Strategic choices
 - 17.1.2.4.3 Weaknesses & competitive threats
- 17.1.3 GENSCRIPT
 - 17.1.3.1 Business overview
 - 17.1.3.2 Products/Services offered
 - 17.1.3.3 Recent developments
 - 17.1.3.3.1 Product/Service launches & approvals
 - 17.1.3.3.2 Deals
 - 17.1.3.3.3 Expansions
 - 17.1.3.4 MnM view
 - 17.1.3.4.1 Key strengths
 - 17.1.3.4.2 Strategic choices
 - 17.1.3.4.3 Weaknesses and competitive threats
- 17.1.4 AGILENT TECHNOLOGIES, INC.
 - 17.1.4.1 Business overview
 - 17.1.4.2 Products/Services offered
 - 17.1.4.3 Recent developments
 - 17.1.4.3.1 Deals
 - 17.1.4.3.2 Expansions
 - 17.1.4.4 MnM view
 - 17.1.4.4.1 Key strengths
 - 17.1.4.4.2 Strategic choices
 - 17.1.4.4.3 Weaknesses & competitive threats

17.1.5 REVVITY, INC.

- 17.1.5.1 Business overview
- 17.1.5.2 Products/Services offered
- 17.1.5.3 Recent developments
 - 17.1.5.3.1 Product/Service launches
 - 17.1.5.3.2 Deals
- 17.1.5.4 MnM view
 - 17.1.5.4.1 Key strengths
 - 17.1.5.4.2 Strategic choices
 - 17.1.5.4.3 Weakness & competitive threats

17.1.6 LONZA

- 17.1.6.1 Business overview
- 17.1.6.2 Products/Services offered
- 17.1.6.3 Recent developments
 - 17.1.6.3.1 Product/Service launches

17.1.7 TECAN TRADING AG

- 17.1.7.1 Business overview
- 17.1.7.2 Products/Services offered
- 17.1.7.3 Recent developments
 - 17.1.7.3.1 Deals

17.1.8 SANGAMO THERAPEUTICS

- 17.1.8.1 Business overview
- 17.1.8.2 Products/Services offered
- 17.1.8.3 Recent developments
 - 17.1.8.3.1 Deals

17.1.9 PRECISION BIOSCIENCES

- 17.1.9.1 Business overview
- 17.1.9.2 Products/Services offered
- 17.1.9.3 Recent developments
 - 17.1.9.3.1 Deals

17.1.10 CELLECTIS S.A.

- 17.1.10.1 Business overview
- 17.1.10.2 Products/Services offered
- 17.1.10.3 Recent developments
 - 17.1.10.3.1 Deals

17.1.11 REGENERON PHARMACEUTICALS, INC.

- 17.1.11.1 Business overview
- 17.1.11.2 Products/Services offered
- 17.1.11.3 Recent developments

- 17.1.11.3.1 Deals
- 17.1.12 AMBSIO
 - 17.1.12.1 Business overview
 - 17.1.12.2 Products/Services offered
- 17.1.13 CREATIVE BIOGENE
 - 17.1.13.1 Business overview
 - 17.1.13.2 Products/Services offered
- 17.1.14 SYNTHIGO
 - 17.1.14.1 Business overview
 - 17.1.14.2 Products/Services offered
 - 17.1.14.3 Recent developments
 - 17.1.14.3.1 Product/Service launches
 - 17.1.14.3.2 Deals
 - 17.1.14.3.3 Expansions
- 17.1.15 TAKARA BIO INC.
 - 17.1.15.1 Business overview
 - 17.1.15.2 Products/Services offered
 - 17.1.15.3 Recent developments
 - 17.1.15.3.1 Deals
 - 17.1.15.3.2 Expansions
- 17.1.16 BIO-TECHNE
 - 17.1.16.1 Business overview
 - 17.1.16.2 Products/Services offered
 - 17.1.16.3 Recent developments
 - 17.1.16.3.1 Deals
 - 17.1.16.3.2 Expansions
- 17.1.17 CARIBOU BIOSCIENCES, INC.
 - 17.1.17.1 Business overview
 - 17.1.17.2 Products/Services offered
 - 17.1.17.3 Recent developments
 - 17.1.17.3.1 Deals
- 17.1.18 BIONEER CORPORATION
 - 17.1.18.1 Business overview
 - 17.1.18.2 Products/Services offered
- 17.1.19 REPROCELL INC.
 - 17.1.19.1 Business overview
 - 17.1.19.2 Products/Services offered
- 17.2 OTHER PLAYERS
 - 17.2.1 ALSTEM INC.

- 17.2.2 NEW ENGLAND BIOLABS
- 17.2.3 INSCRIPTA, INC.
- 17.2.4 BIOCAT GMBH.
- 17.2.5 INTEGRATED DNA TECHNOLOGIES, INC.
- 17.2.6 COBO TECHNOLOGIES APS
- 17.2.7 GENECOPOEIA, INC.
- 17.2.8 HERA BIOLABS
- 17.2.9 STEMCELL TECHNOLOGIES.
- 17.2.10 AXOL BIOSCIENCE LTD.
- 17.2.11 CELLECTA, INC.
- 17.2.12 APPLIED STEMCELL

18 APPENDIX

- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS

I would like to order

Product name: Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/G22CBF77F5FDEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G22CBF77F5FDEN.html>